Galantamine beyond Alzheimer's disease-a fact or artefact?
Ahmed NaguyKhaled HusainBibi AlamiriPublished in: CNS spectrums (2020)
Galantamine is US-Food and Drug Administration FDA-approved for mild-to-moderate Alzheimer's disease. However, its unique pharmacological portfolio speaks to the idea of a pluripotent agent with a broad therapeutic potential. Here, authors briefly discuss these off-label clinical indications synthesizing the extant evidence.